Tag - APTX

Developments

Aptinyx completes enrollment in Phase 2 PTSD trial

Aptinyx (NASDAQ:APTX) completed enrollment for its Phase 2 study of NYX-783 for the treatment of post-traumatic stress disorder (PTSD). The 160 enrolled patients were randomized to receive either placebo, 10 mg of NYX...

June 18, 2020

Developments

Aptinyx begins Phase 2 study of Parkinson’s disease-associated mild cognitive impairment

Aptinyx (NASDAQ:APTX) launched a Phase 2 study of NYX-458 for the treatment of mild cognitive impairment associated with Parkinson’s disease (PD). NYX-458 is an n-methyl-d-aspartate, or NMDA, receptor modulator. The 135...

December 5, 2019

Tag - APTX

Aptinyx completes enrollment in Phase 2 PTSD trial

Aptinyx begins Phase 2 study of Parkinson’s disease-associated mild cognitive impairment

General

More